Table 3.

Relative risks^* (RRs) and 95% confidence intervals (CIs) for the association between pre-diagnostic 25-hydroxy and 1,25-dihydroxy vitamin D levels and ovarian cancer risk in the Nurses’ Health Study (NHS), NHSII, and Women’s Health Study, stratified by polymorphisms in the vitamin D Receptor gene.

	25-hydroxyvitamin D†		1,25-dihydroxyvitamin D†
Polymorhpism	<32ng/mL	≥32 ng/mL	<median	≥median
Fok1
n, cases/controls	166/385	44/137	101/264	108/257
FF	1.0	0.66 (0.34, 1.28)	1.0	1.03 (0.59, 1.81)
Ff	1.0	0.80 (0.45, 1.43)	1.0	1.35 (0.83, 2.19)
ff	1.0	0.49 (0.17, 1.38)	1.0	0.57 (0.24, 1.32)
Ff + ff	1.0	0.71 (0.43, 1.18)	1.0	1.08 (0.71, 1.64)
Bsm1
n, cases/controls	158/369	41/125	94/250	104/243
bb	1.0	0.61 (0.30, 1.27)	1.0	0.89 (0.50, 1.58)
bB	1.0	0.75 (0.41, 1.35)	1.0	1.27 (0.77, 2.08)
BB	1.0	0.70 (0.26, 1.92)	1.0	1.14 (0.47, 2.77)
bB+BB	1.0	0.73 (0.43, 1.22)	1.0	1.23 (0.80, 1.89)
Cdx2
n, cases/controls	160/371	43/132	97/254	105/248
GG	1.0	0.59 (0.36, 0.98)	1.0	1.15 (0.75, 1.74)
GA+AA	1.0	0.91 (0.46, 1.81)	1.0	0.97 (0.55, 1.74)

^*Used unconditional logistic regression adjusting for number of pregnancies, postmenopausal hormone use, oral contraceptive use duration, age at menarche, age, menopausal status at diagnosis, cohort, season of blood collection, body mass index at blood collection, and the interaction of study with oral contraceptive use duration and body mass index.

^†p-heterogeneity across Fok1, Bsm1, and Cdx2 genotypes for 25-hydroxyvitam in D are 0.81, 0.81, and 0.32, respectively and for 1,25-dihydroxyvitam in D are 0.47, 0.53, and 0.65, respectively.